Journal
Blood Advances
Publication Date
12-9-2025
Volume
9
Issue
23
First Page
6092
Last Page
6095
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2025016423
Rights and Permissions
Ahmed S, DiPersio J, Essell J, Diefenbach C, Perales MA, Castilla-Llorente C, Dahiya S, Liu Y, Xu H, Fanton C, Chaudhry S, Lee ZH, Marcondes AMQ, Tagliaferri MA, Zalevsky J, Miklos D, Turtle CJ, McGuirk J. NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. Blood Adv. 2025 Dec 9;9(23):6092-6095. doi: 10.1182/bloodadvances.2025016423. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Ahmed, Sairah; DiPersio, John; and et al., "NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma." Blood Advances. 9, 23. 6092 - 6095. (2025).
https://digitalcommons.wustl.edu/oa_4/6414
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
